Reclaim your health through regenerative medicine

Company information

Company Overview
Company name:
Innovacell GmbH
Head office:
Mitterweg 24, 6020 Innsbruck, Austria
Founded in:
2000 as Innovacell Biotechnologie GmbH
Capital Stock:
228,030
Number of employees:
33

Reclaim your health through regenerative medicine

Managing Directors

Dr. Rainer Marksteiner

Dr. Rainer Marksteiner is co-founder and CSO of Innovacell AG. Since February 2002, Dr. Marksteiner worked as a scientific director in the field of research and product development in the company. Before that, he was a research assistant at the Institute for Biochemical Pharmacology at the University of Innsbruck and at the Dermatology Clinic Innsbruck. Dr. Marksteiner completed his degree study program in microbiology at the Leopold-Franzens-Universität Innsbruck with distinction, and in 1999 he obtained his doctorate in natural sciences with distinction. He has written numerous scientific publications in the field of cell biology.

Colin Lee Novick

Born in South Korea and raised in Japan, Colin L. Novick attended Japanese school and then studied East Asian Studies and Chemistry at Cornell University. After working for three years as a management consultant at Deloitte Tohmatsu Consulting within the Financial Services Industry Group, he joined the M&A department of SMBC Nikko Securities. In 2012, Colin L. Novick co-founded CJ PARTNERS Inc. with Jason David Sieger to assist in the development of Japanese listed companies.

Jason David Sieger

Yasushi Hosono

Reclaim your health through regenerative medicine

What we do

Innovacell is a biotechnology company focused on developing, producing and marketing cell therapies for treating fecal and urinary incontinence. Technologies for isolating, multiplying, using and delivering muscle cells have been developed. Associated patents have already been granted or their applications filed.

Innovacell works according to the rules of “Good Laboratory Practice” (GLP), “Good Manufacturing Practice” (GMP) and “Good Clinical Practice” (GCP). These guidelines ensure that internationally recognized quality standards are met while developing, manufacturing, processing, packaging and storing pharmaceuticals and that customers and patients receive products of the highest quality.

Innovacell is one of the largest producers of autologous (endogenous) in vitro multiplied cells in Europe. Capacity is between 500 and 5,000 units per year, depending on the cell type.

Automation of manufacturing processes is in development. There are two main objectives:

  1. Capacity required in the commercialization phase shall be built up step by step (scale-up).
  2. This capacity shall be divided between five production plants, two in the EU, two in the USA and one in Japan, using a decentralized manufacturing and distribution model (scale-out).

Innovacell has approval to manufacture cell therapy test material for clinical studies. This includes currently the following cell types: autologous skeletal muscle cells, skin fibroblasts, and hair follicle cells.

Innovacell aims to market the products it has developed in the five key European countries (Germany, France, Italy, Spain and the United Kingdom) as well as in Japan and the USA. The goal is to become a global leader in the field of regenerative medicine with a focus on innovative, personalized cell therapies.

Reclaim your health through regenerative medicine

Investors

Innovacell is an equity funded company. The potential of innovative cell therapy, results obtained so far and further development steps all underline the quality of the work accomplished and have convinced both venture capitalists and other investors to support Innovacell.

Since the company’s founding in 2000, the Innovacell management team has been able to raise substantial funds to develop cell therapies in Europe. Furthermore, since 2019, the company has also been supported by Japanese investors in order to advance clinical development for the Asian region, especially Japan.

Innovacell’s operations and clinical development programs are funded by the following highly committed investors with extensive pharmaceutical experience:

  • Ci:z Investment LLP, Japan
  • Eagle Fund SP1 LLP, Japan
  • ID Pharma Group Co., Ltd., Japan
  • Peppermint Grove Ltd., Hong Kong
  • Private investors, Austria, Japan, Taiwan, USA

Working at Innovacell

Become part of our team!

Would you like to contribute to developing and approving a new generation of medicines and play a decisive role in producing new products? Is a positive, collegial working atmosphere important to you? Do you want to take responsibility? Then apply today!

Datenschutzeinstellungen

Wir benötigen Ihre Zustimmung, bevor Sie unsere Website weiter besuchen können. Wir verwenden Cookies und andere Technologien auf unserer Website. Einige von ihnen sind essenziell, während andere uns helfen, diese Website und Ihre Erfahrung zu verbessern. Personenbezogene Daten können verarbeitet werden (z. B. IP-Adressen), z. B. für personalisierte Anzeigen und Inhalte oder Anzeigen- und Inhaltsmessung. Weitere Informationen über die Verwendung Ihrer Daten finden Sie in unserer Datenschutzerklärung. Sie können Ihre Auswahl jederzeit unter Einstellungen widerrufen oder anpassen.